Small-molecule CDK4/6-inhibitors as ribociclib, palbociclib, and abemaciclib have shown the ability to inhibit the growth of ER–positive breast cancer cells, act synergistically with antiestrogens, and reverse endocrine resistance [55–58]. Here, ESR1 is linked to breast carcinoma.